RHOA and pulmonary arterial hypertension: In addition to the inhibition of RhoA-ROCK directly by fasudil, there are many other potential approaches to inhibit the RhoA-ROCK axis in PAH, such as the aminofurazan derivative drug, SB-772077-B, simvastatin [64], resveratrol [67], Compound 3 (trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide) [68] and fasudil dichloroacetate [69].